OPEN QUESTIONS OF PSYCHOTIC DEPRESSION
![](https://ctmd.psypharma.ru/public/journals/1/cover_issue_67_ru_RU.jpg)
Abstract
A literature review was conducted in the PubMed and Google databases. Key words were used: psychotic depression, depression with psychotic features, treatment of psychotic depression. Inclusion criteria: randomized clinical trials (RCTs), meta-analyses and systematic reviews, relevant full-text articles on psychotic depression. Exclusion Criteria: Low quality articles. The terminology of the article corresponds to that used in the publications included in the review. An analysis of publications has shown that psychotic depression is an evolving concept, remains a serious condition, accompanied by high (up to 40% over 15 years) mortality, suicidal risk, difficulty in diagnosis and complexity of therapy. Fluvoxamine monotherapy has been shown to be an effective treatment for psychotic depression. The drug can be considered as an antidepressant of the first choice for the treatment of depression with delusions from the SSRI group. The effect of fluvoxamine on delirium is associated with its high affinity for Sigma-1 receptors.
Keywords
psychotic depression, epidemiology, diagnostics, therapy, fluvoxamine
References
- Jääskeläinen E., Juola T., Korpela H. et al. Epidemiology of psychotic depression – systematic review and meta-analysis // Psychological Medicine. – 2018. – Vol. 48 (6). – Рp. 905–918. – https://doi.org/10.1017/S0033291717002501
- Ohayon M.M., Schatzberg A.F. Prevalence of depressive episodes with psychotic features in the general population // Am J Psychiatry. – 2002. – Vol. 159 (11). – Рp. 1855–1861. – https://doi.org/10.1176/appi.ajp.159.11.1855
- Rothschild A.J. Challenges in the treatment of major depressive disorder with psychotic features // Schizophr Bull. – 2013. – Vol. 39 (4). – Рp. 787–796. – https://doi.org/10.1093/schbul/sbt046
- Costa F.B.P.D., Trachtenberg E., Boni A., Primo de Carvalho Alves L., Magalhães P.V.D.S., Rocha N.S. Psychotic depression in hospitalized patients: Longitudinal outcomes of psychotic vs. nonpsychotic depression among inpatients // J Psychiatr Res. – 2020. – Vol. 129. – Pp. 73–79. – https://doi.org/10.1016/j.jpsychires.2020.06.002
- Flint A.J., Meyers B.S., Rothschild A.J., Whyte E.M., Mulsant B.H., Rudorfer M.V., Marino P., STOP-PD II Study Group. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II // BMC Psychiatry. – 2013. – Vol. 25. – 38. – https://doi.org/10.1186/1471-244X-13-38
- Vythilingam M., Chen J., Bremner J.D., Mazure C.M., Maciejewski P.K., Nelson J.C. Psychotic depression and mortality // Am J Psychiatry. – 2003. – Vol. 160 (3). – Pp. 574–576. – https://doi.org/10.1176/appi.ajp.160.3.574
- Paljärvi T., Tiihonen J., Lähteenvuo M., Tanskanen A., Fazel S., Taipale H. Mortality in psychotic depression: 18-year follow-up study // The British Journal of Psychiatry. – 2023. – Vol. 222 (1). – Pp. 37–43. – https://doi.org/10.1192/bjp.2022.140
- Петрова Н.Н., Столяров А.Р. Психотическая депрессия с позиции персонифицированного подхода // Российский психиатрический журнал. – 2021. – № 1. – С. 82–92. – https://doi.org/10.47877/1560-957X-2021-10109
- Dubovsky S.L., Ghosh B.M., Serotte J.C., Cranwell V. Psychotic Depression: Diagnosis, Differential Diagnosis, and Treatment // Psychother Psychosom. – 2021. – Vol. 90 (3). – Pp. 160–177. – https://doi.org/10.1159/000511348
- Tandon R. Conceptualizing psychotic disorders: don’t throw the baby out with the bathwater // World Psychiatry. – 2016. – Vol. 15 (2). – Pp. 133–34. – https://doi.org/10.1002/wps.20338
- Morgan C., Lappin J., Heslin M., Donoghue K., Lomas B., Reininghaus U., Onyejiaka A., Croudace T., Jones P.B., Murray R.M., Fearon P., Doody G.A., Dazzan P. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study // Psychol Med. – 2014. – Vol. 44 (13). – Pp. 2713–2726. – https://doi.org/10.1017/S0033291714000282
- van Os J., Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population//World Psychiatry. – 2016. – Vol. 15 (2). – Pp. 118–124. – https://doi.org/10.1002/wps.20310
- Keller J., Schatzberg A. F., Maj M. Current Issues in the Classification of Psychotic Major Depression // Schizophr Bull. – 2007. – Vol. 33. – Pр. 877–885. – https://doi.org/10.1093/schbul/sbm065
- Nelson J.C., Bickford D., Delucchi K., Fiedorowicz J.G., Coryell W.H. Risk of psychosis in recurrent episodes of psychotic and nonpsychotic major depressive disorder: a systematic review and meta-analysis // Am J Psychiatry. – 2018. – Vol. 175. – Pp. 897–904. https://doi.org/10.1176/appi.ajp.2018.17101138
- Heslin M., Lomas B., Lappin J.M., Donoghue K., Reininghaus U., Onyejiaka A. et al. Diagnostic change 10 years after a first episode of psychosis // Psychol Med. – 2015. – Vol. 45. – Pp. 2757–2769. – https://doi.org/10.1017/S0033291715000720
- McGorry P.D., Hartmann J.A., Spooner R., Nelson B. Beyond the “at risk mental state” concept: Transitioning to transdiagnostic psychiatry // World Psychiatry. – 2018. – Vol. 17 (2). – Pp. 133–142. – https://doi.org/10.1002/wps.20514
- Heslin M., Young A.H. Psychotic major depression: challenges in clinical practice and research // The British Journal of Psychiatry. – 2018. – Vol. 212. – Pp. 131–133. https://doi.org/10.1192/bjp.2017.43
- Ruggero C.J., Kotov R., Carlson G.A., Tanenberg-Karant M., González D.A., Bromet E.J. Diagnostic consistency of major depression with psychosis across 10 years // J Clin Psychiatry. – 2011. – Vol. 72 (9). – Pp. 1207–1213. – https://doi.org/10.4088/JCP.10m06774
- Østergaard S.D., Pedersen C.H., Uggerby P., Munk-Jørgensen P., Rothschild A.J., Larsen J.I., Gøtzsche C., Søndergaard M.G., Bille A.G., Bolwig T.G., Larsen J.K., Bech P. Clinical and psychometric validation of the psychotic depression assessment scale // J Affect Disord. – 2015. – Vol. 1 (173). – Pp. 261–268. – https://doi.org/10.1016/j.jad.2014.11.012
- Carlson G.A. Affective disorders and psychosis in youth // Child Adolesc Psychiatr Clin N Am. – 2013. – Vol. 22 (4). – Pp. 569–580. – https://doi.org/10.1016/j.chc.2013.04.003
- Wijkstra J., Burger H., van den Broek W.W., Birkenhäger T.K., Janzing J.G., Boks M.P., Bruijn J.A., van der Loos M.L., Breteler L.M., Verkes R.J., Nolen W.A. Long-term response to successful acute pharmacological treatment of psychotic depression // J Affect Disord. – 2010. – Vol. 123 (1–3). – Pp. 238–242. – https://doi.org/10.1016/j.jad.2009.10.014
- Tohen M., Khalsa H.K., Salvatore P., Vieta E., Ravichandran C., Baldessarini R.J. Two-year outcomes in first-episode psychotic depression the McLean-Harvard First-Episode Project // J Affect Disord. – 2012. – Vol. 136 (1–2). – Pp. 1–8. – https://doi.org/10.1016/j.jad.2011.08.028
- Coryell W., Leon A., Winokur G., Endicott J., Keller M., Akiskal H., Solomon D. Importance of psychotic features to long-term course in major depressive disorder // Am J Psychiatry. – 1996. – Vol. 153 (4). – Pp. 483–489. – https://doi.org/10.1176/ajp.153.4.483
- Биологические методы терапии психических расстройств (доказательная медицина – клинической практике) / под ред. С.Н. Мосолова. – М.: Социально-политическая мысль, 2012. – 1073 с.
- Мосолов С.Н., Костюкова Е.Г. Лечение больных с рекуррентным депрессивным расстройством // Психиатрия: национальное руководство / под ред. Н.Г. Незнанова, Ю.А. Александровского. – М.: Эхо, 2018. – С. 347–378.
- Farahani A., Correll C.U. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment // J Clin Psychiatry. – 2012. – Vol. 73 (4). – Рp. 486–496. – https://doi.org/10.4088/JCP.11r07324
- Anthonis E., Sienaert P. Farmacotherapeutische behandeling van psychotische depressie: een overzicht [Farmacotherapeutic treatment of psychotic depression: a review] // Tijdschr Psychiatr. – 2021. – Vol. 63 (5). – Pp. 358–365. – PMID: 34043225
- Gabriel A. Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study // Neuropsychiatr Dis Treat. – 2013. – Vol. 9. – Pp. 485–492. – https://doi.org/10.2147/NDT.S42745
- König F., Hippel C.V., Petersdorff T., Neuhöffer-Weiss M., Wolfersdorf M., Kaschka W.P. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression // Neuropsychobiology. – 2001. – Vol. 43. – Pp. 170– 174. – https://doi.org/10.1159/000054886
- Konstantinidis A., Hrubos W., Nirnberger G., Windhager E., Lehofer M., Aschauer H. et al. Quetiapine in combination with citalopram in patients with unipolar psychotic depression // Prog Neuropsychopharmacol Biol Psychiatry. – 2007. – Vol. 31. – Pp. 242–247. – https://doi.org/10.1016/j.pnpbp.2006.07.002
- Matthews J.D., Bottonari K.A., Polonia L.M., Mischoulon D., Dording C.M., Irvin R. et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses // J Clin Psychiatry. – 2002. – Vol. 63. – Pp. 1164–1170. – https://doi.org/10.4088/jcp.v63n1212
- Meyers B.S., Flint A.J., Rothschild A.J., Mulsant B.H. A double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression – the stop-PD study // Arch Gen Psychiatry. – 2009. – Vol. 66. – Pp. 838–847. – https://doi.org/10.1001/archgenpsychiatry.2009.79
- Депрессивный эпизод. Рекуррентное депрессивное расстройство. Клинические рекомендации. Взрослые // Электронное издание. М.: Минздрав РФ, 2021. – 89 с. – URL: https://cr.minzdrav.gov.ru/recomend/301_2 (дата обращения 12.02.2023).
- Mendlewicz J. Efficacy of fluvoxamine in severe depression// Drugs. – 1992. – Vol. 43 (2). – P. 32–37; discussion 37-9. – https://doi.org/10.2165/00003495-199200432-00006
- Gatti F., Bellini L., Gasperini M., Perez J., Zanardi R., Smeraldi E. Fluvoxamine alone in the treatment of delusional depression // Am J Psychiatry. – 1996. – Vol. 153 (3). – Pp. 414–416. – https://doi.org/10.1176/ajp.153.3.414
- Zanardi R., Franchini L., Gasperini M., Smeraldi E., Perez J. Longterm treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study // Int Clin Psychopharmacol. – 1997. – Vol. 12 (4). – Pp. 195–197. – https://doi.org/10.1097/00004850-199707000-00002
- Hedlund J.L., Vieweg B.W. The Hamilton rating scale for depression: A comprehensive review // Journal of Operational Psychiatry. – 1979. – Vol. 10. – Pp. 149–165.
- Kendler K.S., Glazer W.M., Morgenstern H. Dimensions of delusional experience // Am J Psychiatry. – 1983. – Vol. 140 (4). – Pp. 466–469. – https://doi.org/10.1176/ajp.140.4.466
- Zanardi R., Franchini L., Gasperini M., Lucca A., Smeraldi E., Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study // J Clin Psychopharmacol. – 1998. – Vol. 18 (6). – Pp. 441–446. – https://doi.org/10.1097/00004714-199812000-00004
- Bellini L., Gasperini M., Gatti F., Franchini L., Smeraldi E. A double blind study with fluvoxamine vs. desipramine combined with placebo or haloperidol in delusional depression // Crit Issues Treat Affect Disord. –1994. – Vol. 9. – Pp. 32–36.
- Zanardi R., Franchini L., Serretti A., Perez J., Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study // J Clin Psychiatry. – 2000. – Vol. 61 (1). – Pp. 26–29. – https://doi.org/10.4088/jcp.v61n0107
- Furuse T., Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors // Ann Gen Psychiatry. – 2009. – Vol. 21 (8). – Art. 26. – https://doi.org/10.1186/1744-859X-8-26
- Stahl S.M. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor // CNS Spectr. – 2005. – Vol. 10 (4). – Pp. 319–323. – https://doi.org/10.1017/s1092852900022641
- Fishback J.A., Robson M.J., Xu Y.T., Matsumoto R.R. Sigma receptors: potential targets for a new class of antidepressant drug // Pharmacol Ther. – 2010. – Vol. 127 (3). – Pp. 271–282. – https://doi.org/10.1016/j.pharmthera.2010.04.003
- Albayrak Y., Hashimoto K. Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders // Adv Exp Med Biol. – 2017. – Vol. 964. – Pp. 153–161. – https://doi.org/10.1007/978-3-319-50174-1_11
- Smith S.B. Introduction to Sigma Receptors: Their Role in Disease and as Therapeutic Targets // Adv Exp Med Biol. – 2017. – Vol. 964. – Pp. 1–4. – https://doi.org/10.1007/978-3-319-50174-1
- Morales-Lázaro S.L., González-Ramírez R., Rosenbaum T. Molecular Interplay Between the Sigma-1 Receptor, Steroids, and Ion Channels // Front Pharmacol. – 2019. – Vol. 24 (10). – Art. 419. – https://doi.org/10.3389/fphar.2019.00419
- Kishimoto A., Todani A., Miura J., Kitagaki T., Hashimoto K. The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report // Ann Gen Psychiatry. – 2010. – Vol. 21 (9). – Art. 23. – https://doi.org/10.1186/1744-859X-9-23
- Serretti A., Lattuada E., Zanardi R., Franchini L., Smeraldi E. Patterns of symptom improvement during antidepressant treatment of delusional depression // Psychiatry Res. – 2000. – Vol. 94 (2). – Pp. 185–190. – https://doi.org/10.1016/s0165-1781(00)00139-6
- Kelstrup A.M., Videbech P. [Unipolar psychotic depression] // Ugeskr Laeger. – 2021. – Vol. 183 (38). – Art. V04210312.